Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity

Abstract

In this article, we discuss the advantages and progress made with heterologous prime–boost vaccination strategies. Although the consecutive use of DNA and recombinant viral vectors induce greatly enhanced and sustained levels of both cell-mediated and humoral immunity in preclinical models, the results have not yet been translated to clinical use. Despite this, there is still a high level of optimism that these strategies offer the best hope for the development of vaccines against diseases for which there are no effective vaccines currently available. In this article, we discuss how prime–boost immunization can elicit improved mucosal immunity, how ‘mucosal’ regimes also elicit ‘high-quality’ (high-avidity) T-cell responses to vaccine antigens, and the use of cytokines/chemokines as genetic adjuvants.

Keywords::

• cell-mediated immunity
• costimulatory molecule
• DNA vaccine
• HIV
• mucosal vaccine
• prime–boost
• T-cell avidity

Financial & competing interests disclosure

This work was supported by the NIH HIV Vaccine Design and Development Team award N01-AI-05395 (Ian A Ramshaw), the Australian National Health and Medical Research Council program grant award 299907 (Ian A Ramshaw) and project grant award 525431 (Charani Ranasinghe). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.